Setipiprant

Setipiprant (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTH2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

However, following research that implicated prostaglandin D2 in the pathogenesis of androgenetic alopecia (male pattern baldness), Setipiprant was subsequently pursued for this indication. It reached phase II clinical trials for this application but was discontinued in December 2019.

Pharmacology

Setipiprant is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTH2). Prostaglandin D2 is a mediator of inflammation in the airways and also has been implicated in the pathogenesis of androgenetic alopecia (male pattern baldness).

Clinical trials

Setipiprant has undergone Phase II clinical trials by Allergan as a treatment for androgenetic alopecia in men, but the trials were terminated in December 2019 due to the drug's failure to outperform a placebo.

See also

• Prostaglandin D2 receptor 2
• Androgenetic alopecia
• Actelion

References

• 
  Setipiprant